Foss, F M <br/><br/>
Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.  [electronic resource] 

 -  Clinical lymphoma  Mar 2001 
 - 298-302 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1526-9655 
<br/><br/><label>Standard No.: </label>10.3816/clm.2001.n.005  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Combined Modality Therapy<br/>Dexamethasone--therapeutic use<br/>Diphtheria Toxin--adverse effects<br/>Drug Hypersensitivity--etiology<br/>Female<br/>Glucocorticoids--therapeutic use<br/>Humans<br/>Immunosuppressive Agents--adverse effects<br/>Immunotoxins--adverse effects<br/>Interleukin-2--adverse effects<br/>Lymphocytes--immunology<br/>Lymphoma, T-Cell, Cutaneous--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Prednisone--therapeutic use<br/>Premedication<br/>Recombinant Fusion Proteins--adverse effects<br/>Skin Neoplasms--drug therapy<br/>Syndrome<br/>Treatment Outcome